Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
aclarubicin (2 trials)
cytarabine (cytosar-u) (4 trials)
decitabine (dacogen) (2 trials)
Filgrastim (neupogen) (2 trials)
omacetaxine (synribo) (2 trials)
sitagliptin (januvia) (1 trial)
autologous cd19/cd22 chimeric antigen receptor t-cells (1 trial)
autologous hematopoietic stem cells (1 trial)
azacitidine (vidaza) (4 trials)
chidamide (1 trial)
cladribine (leustatin) (2 trials)
inotuzumab ozogamicin (besponsa) (1 trial)
venetoclax (venclexta) (6 trials)
Leukemia (Phase 3)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, T-Cell (Phase 3)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)
Trials (11 total)
Trial APIs (13 total)